Hing C Wong

CEO Hing C Wong buys 113,879 shares at $1.40 via placement; holds 615,790 post-transaction amid poor track record.

Hing C Wong, CEO, purchased 113,879 shares at $1.40 on 2026-05-22 for $160,000.00, increasing holdings to 615,790 shares (+22.7%). However, this transaction is flagged as a private placement or registered direct offering, not a discretionary open-market purchase, so it should not be read as a conviction-driven buying signal. Wong's cross-ticker track record shows 3 prior open-market buys with an average 90-day return of -62.2% and a 90d win rate of 0.00%, while his same-ticker history at HCWB shows two prior buys (2025-05-16 and 2025-05-08) both resulted in significant losses over 90 days (-41.7% and -82.6% respectively). HCW Biologics faces material headwinds: annual revenue growth was -97.9%, full-year net income was negative, and the company's market cap is only $13.1M against quarterly revenue of $6.5M. The stock is currently -78.0% from its 52-week high of $8.82, though it has rallied +341.9% over the past 30 days. A cluster of 2 other insiders also bought within 14 days, but the non-discretionary nature of this placement and the insider's poor historical timing at this ticker limit the significance of this filing.

CEO Wong Hing C bought 8,054 shares at $7.45 on 2025-05-16 as part of cluster buy by 5 other insiders; stock down 81.5% from 52-week high.

CEO Wong Hing C purchased 8,054 shares at $7.45 on 2025-05-16, increasing holdings from 493,857 to 501,911 shares. This transaction occurs within a broader cluster pattern in which 5 other insiders also bought within the past 14 days, suggesting coordinated insider activity. The stock is currently trading at $9.18, down 81.5% from its 52-week high of $49.60, though up 30.2% over the past 30 days. The company faces material headwinds: it reported revenue of $5,065.00 in the latest quarter and is unprofitable with a negative net income of $-2,196,875.00 and annual revenue decline of -9.7%, placing a $13.2M market cap. The CEO's cross-ticker track record shows only 2 prior open-market buys with no measurable well-timed outcomes, and his same-ticker history at HCWB includes a buy 8 days prior (on 2025-05-08) whose outcome remains unmeasurable. The rapid succession of insider purchases in an unprofitable, revenue-declining company warrants examination into whether these acquisitions reflect opportunistic positioning at depressed valuation levels or internal directional signals about the business.

CEO Wong Hing C buys 92,500 shares at $26.00 for $2,405,000; stock now trades at $6.18 (-87.5% from 52-week high) in cluster pattern with 5 other insiders.

Wong Hing C, CEO of HCW Biologics, acquired 92,500 shares at $26.00 on 2025-05-08, increasing his holdings by 23.0% to 493,857 shares post-transaction. This open-market purchase arrives amid severe price deterioration—the stock has collapsed -87.5% from its 52-week high of $49.60 to a current price of $6.18, and declined -68.3% over the past 90 days. Critically, the purchase occurs within a cluster of 5 other insider buys in the same 14-day window, signaling coordinated accumulation at depressed levels. Contemporaneously, the company is unprofitable (negative $-3,902,288.00 net income) with contracting revenue (annual growth of -9.7%), creating a disconnect between insider accumulation and deteriorating fundamentals that warrants scrutiny of the underlying investment thesis.